Enhancing procedural quality and efficiency of methacholine bronchial challenge tests in patients with suspected cough-variant asthma: a quasi-experimental study utilizing nurse–patient communication and respiratory training - Top-Institutions - MDSpire

Enhancing procedural quality and efficiency of methacholine bronchial challenge tests in patients with suspected cough-variant asthma: a quasi-experimental study utilizing nurse–patient communication and respiratory training

  • By

  • Yu Hu

  • Hailun Wang

  • Chang Tan

  • Yu He

  • Jin Zhu

  • Shi Chen

  • Tian Zhao

  • Enhong Liu

  • Ying Chen

  • Sisi Chen

  • Beibei Zhang

  • Hongmei Xiang

  • Fajiu Li

  • Xuecun Wang

  • July 1, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Pulmonology
    • Lung Surgery

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Pulmonology
    • Lung Surgery

  • #3

    West China Hospital of Sichuan University
    West China Hospital of Sichuan University

    Chengdu, Sichuan

    Key Differentiators

    • Pulmonology

  • #4

    Tampere University Hospital
    Tampere University Hospital

    Tampere, Finland

    Key Differentiators

    • Pulmonology

  • #5

    University of Leipzig
    University of Leipzig

    Leipzig, Germany

    Key Differentiators

    • Pulmonology

Original Source(s)

Enhancing procedural quality and efficiency of methacholine bronchial challenge tests in patients with suspected cough-variant asthma: a quasi-experimental study utilizing nurse–patient communication and respiratory training

  • by Yu Hu, Hailun Wang, Chang Tan, Yu He, Jin Zhu, Shi Chen, Tian Zhao, Enhong Liu, Ying Chen, Sisi Chen, Beibei Zhang, Hongmei Xiang, Fajiu Li, Xuecun Wang

  • July 1, 2026

Related Content

Case Report: Pulmonary artery biopsy findings in a patient with a BMPR2 variant-associated pulmonary arterial hypertension

Predictive validity of SOFA-2: analytical and contextual considerations

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min